Cagrilintide Overview

Cagrilintide is a synthetic, long-acting analog of the naturally occurring peptide amylin. It is studied in laboratory and preclinical models for its ability to activate amylin and calcitonin receptors, contributing to the regulation of metabolic and neuroendocrine pathways. Research has examined its role in modulating satiety signals, gastric emptying, and systemic metabolic processes.

Granhall C. et al. (2019).

History

Research into amylin biology began in the late 20th century with its identification as a pancreatic peptide co-secreted with insulin. Native amylin was found to influence metabolic regulation but was limited by rapid degradation. Cagrilintide was later developed as a stabilized analog with prolonged receptor activity, providing a research tool for studying calcitonin receptor family signaling and endocrine cross-talk in metabolic systems.

Bergmann N.C. et al. (2019).

Cagrilintide Structure

CAS #: 1415456-99-3

Molecular Formula: C₂₉₄H₄₆₆N₈₄O₈₈S₂

Molecular Weight: 6781.6 g/mol

PubChem ID: 137465331

Research Findings

Cagrilintide has been studied in metabolic, endocrine, and systemic models, with research highlighting its role in appetite regulation, energy balance, and weight-related pathways. Studies also report activity in amylin receptor signaling, glucose regulation, and metabolic homeostasis in preclinical and clinical settings.

Key Areas of Research::

• Metabolic: appetite, energy balance, weight regulation

• Endocrine: amylin signaling, glucose control

• Systemic: metabolic homeostasis, resilience, recovery

Together, these findings suggest broad experimental potential for Cagrilintide across metabolic, endocrine, and systemic pathways. By engaging amylin receptor biology and influencing appetite and glucose regulation, Cagrilintide provides a versatile platform for research into metabolic balance, weight biology, and systemic regulation in laboratory models.

Lau D.C.W. et al., 2021

References

Granhall C. et al. (2019). Cagrilintide, a long-acting amylin analog, and its effects on metabolic regulation in research models. Diabetes Obes Metab, 21(10):2076–2084.

Bergmann N.C. et al. (2019). Mechanistic insights into Cagrilintide as a calcitonin receptor agonist in metabolic research. Diabetes Obes Metab, 21(10):2085–2095.

Mullard A. (2020). Next-generation metabolic peptides: focus on amylin analogs like Cagrilintide. Nat Rev Drug Discov, 19(1):4–6.